• Antiparkinson Agents, Benztropine Mesylate
    Dosage form: Tablet
    Strength: 2mg
    Indications/Special comments: Adjunctive treatment of all forms of Parkinsonian syndrome. May be used as monotherapy or combined with other antiParkinsonian agents (e.g., carbidopa-levodopa). Control of extrapyramidal reactions (e.g., acute dystonia) induced by antipsychotic agents (e.g., phenothiazines). Does not alleviate symptoms of tardive dyskinesia, and in some instances may aggravate them. Use not recommended.
    Dosage Administration: Adult: 0.5 – 1mg daily usually at bedtime, generally increased, max. 6mg daily; usual maintenance dose 1 – 4mg daily in single or divided dose; Elderly: preferably lower end of range. Children: Use with caution in children >3 years of age because of adverse anticholinergic effects. Safety and efficacy not established in children <3 years of age.
    View full drug info
  • Antiparkinson Agents, Benztropine Mesylate
    Dosage form: Injection
    Strength: 1mg/ml
    Indications/Special comments: Adjunctive treatment of all forms of Parkinsonian syndrome. May be used as monotherapy or combined with other antiParkinsonian agents (e.g., carbidopa-levodopa). Control of extrapyramidal reactions (e.g., acute dystonia) induced by antipsychotic agents (e.g., phenothiazines). Does not alleviate symptoms of tardive dyskinesia, and in some instances may aggravate them. Use not recommended.
    Dosage Administration: IM or IV: 1 – 2mg repeated if symptoms reappear; Elderly: preferably lower end of range. Children: Use with caution in children >3 years of age because of adverse anticholinergic effects. Safety and efficacy not established in children <3 years of age.
    View full drug info
  • Antineoplastics and Related Agents, Busulfan
    Dosage form: Tablet
    Strength: 2mg
    Indications/Special comments: Chronic myeloid leukaemia, conditioning regimens for bone marrow transplantation.
    Dosage Administration: (Refer to individual protocols); For remission induction of CML: Adult: 4 - 8mg/day (may be as high as 12mg/day). Child: 0.06 - 0.12mg/kg/day or 1.8 - 4.6mg/m2/day; BMT marrow –ablative conditioning regimen: Adult and Child: 1mg/kg/dose every 6 hours for 16 doses.
    View full drug info
  • Antineoplastics and Related Agents, Bortezomib
    Dosage form: Injection
    Strength: 3.5mg
    Indications/Special comments: Multiple myeloma (as initial therapy or after progression); with melphalan and prednisone. Mantle cell lymphoma.
    Dosage Administration: Previously Untreated Multiple Myeloma: IV: SC: Adults: 1.3mg/m2 twice weekly for Cycles 1 – 4 (days 1, 4, 8, 11, 22, 25, 29 and 32; no treatment during cycle 3), then once weekly for Cycles 5 – 9 (days 1, 8, 22, and 29; no treatment during Cycle 7); further cycles/doses depend on response and toxicity. Previously Untreated Mantle Cell Lymphoma:1.3mg/m2 twice weekly on days 1, 4, 8, and 11, followed by a 10–day rest (days 12 – 21); repeat for 5 additional cycles; further cycles/doses depend on response and toxicity. Relapsed Multiple Myeloma and Mantle Cell Lymphoma: 1.3mg/m2 twice weekly for 2 wk (days 1, 4, 8, and 11), followed by a 10–day rest; further cycles/doses depend on response and toxicity. For patients with multiple myeloma who have previously responded to bortezomib therapy and who have relapsed =6 months after prior bortezomib therapy can be started on their last tolerated dose; dose should be given twice weekly (days 1, 4, 8, and 11) every 3 wk for a maximum of 8 cycles.
    View full drug info
  • Antineoplastics and Related Agents, Bleomycin
    Dosage form: Powder for Injection
    Strength: 15mg
    Indications/Special comments: Adjunct to surgery and radiotherapy in palliative treatment of Hodgkin and non-Hodgkin lymphomas; reticulum cell sarcoma and lymphoma; carcinomas of the head, neck, larynx, cervix, penis, skin, vulva, testicles and including embryonal cell carcinoma, choriocarcinoma and teratoma; malignant effusions.
    Dosage Administration: Adult and Child: Single agent therapy: I.M, I.V, SC: Squamous cell carcinoma, lymphoma, testicular carcinoma: 0.25 - 0.5 units/kg (10 - 20 units/m2) 1 - 2 times/week. Combination agent therapy: I.M, I.V: 3 - 4 units/m2. I.V: ABVD: 10 units/m2 on days 1 and 15. Pleural sclerosing: 60 - 240 units as a single infusion.
    View full drug info
  • Antineoplastics and Related Agents, Bicalutamide
    Dosage form: Tablet
    Strength: 50mg
    Indications/Special comments: Metastatic prostate carcinoma in conjunction with luteinizing hormone–releasing hormone (LHRH) analogs (goserelin, leuprolide).
    Dosage Administration: Adults: 50mg once daily (must be given concurrently with LHRH analog).
    View full drug info
  • Antineoplastics and Related Agents, Bevacizumab
    Dosage form: Injection
    Strength: 100mg/4ml; 400mg/16ml
    Indications/Special comments: Metastatic colorectal cancer as a component of multidrug therapy.
    Dosage Administration: IV: Adult: 5 - 10mg/kg every 2 weeks.
    View full drug info
  • Antihistamines and Antiallergics, Bilastine
    Dosage form: Tablet
    Strength: 20mg
    Indications/Special comments: Symptomatic relief of allergic rhinoconjunctivitis and urticaria.
    Dosage Administration: Child 12 – 17 years: 20 mg once daily. Adult: 20 mg once daily.
    View full drug info
  • Antiglaucoma Agents, Brinzolamide + Timolol Maleate
    Dosage form: Eye Drop
    Strength: 1% + 0.5%
    Indications/Special comments: Open-angle glaucoma and other forms of ocular hypertension.
    Dosage Administration: Children over 2 years old and adults: 1 drop 2 times daily.
    View full drug info
  • Antiglaucoma Agents, Brinzolamide + Brimonidine Tartrate
    Dosage form: Eye Drop
    Strength: 1% + 0.2%
    Indications/Special comments: Reduction of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction.
    Dosage Administration: One drop in the affected eye(s) two times daily.
    View full drug info